D. Goldsmith

Through the looking glass: the protein science of biosimilars

M. Kuhlmann, A. Covic, D. Goldsmith, 2007, Clinical and Experimental Nephrology.

Biosimilars: Current Status

M. Kuhlmann, A. Covic, D. Goldsmith, 2007 .

Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.

M. Aapro, P. Gascón, D. Goldsmith, 2022, Critical reviews in oncology/hematology.

Biosimilars: it’s not as simple as cost alone

S. Roger, S. D. Roger, D. Goldsmith, 2008, Journal of clinical pharmacy and therapeutics.

Immunogenicity of biopharmaceuticals.

Huub Schellekens, M. Kessler, H. Schellekens, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future.

David Goldsmith, D. Goldsmith, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Contents 2 Metformin Adjuvant Therapy to Counteract Metabolic Side Effects of Atypical Antipsychotics

A. Moore, M. Mroczkowski, D. Goldsmith, 2013 .

Biosimilars: uncharted territory.

F. Locatelli, D. Goldsmith, 2007, Journal of nephrology.